Phase II Study of RAD001 Monotherapy in Patients With Unresectable Adenoid Cystic Carcinoma

被引：0
|
作者：
Kim, D. [1 ]
Shin, S. [2 ]
Kang, J. [3 ]
Cho, B. [4 ]
Kim, H. [5 ]
Jung, J. [6 ]
Park, K. [7 ]
Kwon, J. [8 ]
Hang, J. [9 ]
Bang, Y. [1 ]
机构：
[1] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
[2] Kosin Univ, Gospel Hosp, Dept Internal Med, Pusan, South Korea
[3] Catholic Univ, Dept Internal Med, Seoul St Marys Hosp, Seoul, South Korea
[4] Yonsei Canc Ctr, Dept Internal Med, Seoul, South Korea
[5] Vet Hosp, Dept Internal Med, Seoul, South Korea
[6] Pusan Natl Univ Hosp, Dept Internal Med, Pusan, South Korea
[7] Keimyung Univ, Dept Internal Med, Dongsan Med Ctr, Taegu, South Korea
[8] Hallym Univ, Med Ctr, Dept Internal Med, Seoul, South Korea
[9] Natl Canc Ctr, Ctr Lung Canc, Ilsan, South Korea
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)72144-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S544 / S544
页数：1
相关论文
共 50 条
  • [21] Final results of a phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium.
    Milowsky, M. I.
    Regazzi, A. M.
    Garcia-Grossman, I. R.
    Trout, A.
    Flaherty, A.
    Gerst, S.
    Al-Ahmadie, H.
    Ostrovnaya, I.
    Bajorin, D. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] A phase I/II study of the oral mTOR inhibitor RAD001 in patients with advanced hematologic malignancies.
    Yee, KWL
    Wierda, W
    O'Brien, S
    Thomas, D
    Kurzrock, R
    Fayad, LE
    Hagemeister, FB
    Cortes, J
    Prestifilippo, K
    Szatrowski, TP
    Kantarjian, HM
    Giles, FJ
    BLOOD, 2004, 104 (11) : 287B - 287B
  • [23] THE COMBINATION EVEROLIMUS (RAD001) PLUS SORAFENIB IS SUPERIOR TO SORAFENIB MONOTHERAPY IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA
    Piguet, A. -C.
    Radojevic, V.
    Afthinos, M.
    Hora, C.
    Ledermann, M.
    Saar, B.
    Dufour, J. -F.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S199 - S199
  • [24] Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients
    Su Jin Lee
    Jongtae Lee
    Jeeyun Lee
    Se Hoon Park
    Joon Oh Park
    Young Suk Park
    Ho Yeong Lim
    Kyoung-Mee Kim
    In-Gu Do
    Sin-Ho Jung
    Dong-Seok Yim
    Won Ki Kang
    Investigational New Drugs, 2013, 31 : 1580 - 1586
  • [25] Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients
    Lee, Su Jin
    Lee, Jongtae
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Kim, Kyoung-Mee
    Do, In-Gu
    Jung, Sin-Ho
    Yim, Dong-Seok
    Kang, Won Ki
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (06) : 1580 - 1586
  • [26] THE ENDORAD TRIAL: RAD001 (EVEROLIMUS) MONOTHERAPY AS SECOND LINE OR THIRD LINE TREATMENT OF ADVANCED ENDOMETRIAL CARCINOMA: A PHASE II TRIAL OF GINECO GROUP
    Ray-Coquard, I.
    Plantade, A.
    Petit, T.
    Lebrun-Jezekova, D.
    Lavau-Denes, S.
    Cretin, J.
    Priou, F.
    Paraiso, D.
    Slimane, K.
    Alexandre, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 305 - 305
  • [27] A phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma
    Harzstark, A. L.
    Rosenberg, J. E.
    Weinberg, V. K.
    Sun, J.
    Ryan, C. J.
    Lin, A. M.
    Fong, L.
    Brocks, D. R.
    Small, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] A phase II study of dovitinib in patients with recurrent or metastatic adenoid cystic carcinoma (ACC).
    Dillon, Patrick Michael
    Petroni, Gina R.
    Moskaluk, Chris
    Fracasso, Paula M.
    Douvas, Michael G.
    Perez, Jose Ricardo
    Varhegyi, Nikole
    Zaja-Milatovic, Snjezana
    Thomas, Christopher Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Phase II study of axitinib in patients with progressive, recurrent/metastatic adenoid cystic carcinoma
    Ho, Alan Loh
    Sherman, Eric Jeffrey
    Fury, Matthew G.
    Baxi, Shrujal S.
    Haque, Sofia
    Sima, Camelia S.
    Antonescu, Cristina R.
    Katabi, Nora
    Pfister, David G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma
    Tchekmedyian, Vatche
    Sherman, Eric J.
    Dunn, Lara
    Tran, Crystal
    Baxi, Shrujal
    Katabi, Nora
    Antonescu, Cristina R.
    Ostrovnaya, Irina
    Haque, Sofia S.
    Pfister, David G.
    Ho, Alan L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (18) : 1529 - 1537
12345